Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia

Haematologica

Volumn 97, Issue 5, 2012, Pages 739-742

  Walter, Roland B ^a,b   Medeiros, Bruno C ^c   Powell, Bayard L ^d   Schiffer, Charles A ^e   Appelbaum, Frederick R ^a,b   Estey, Elihu H ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c STANFORD UNIVERSITY   (United States)

^d WAKE FOREST SCHOOL OF MEDICINE   (United States)

^e WAYNE STATE UNIVERSITY   (United States)

Author keywords

Acute myeloid leukemia; Gemtuzumab ozogamicin; Induction; Older adults; Post remission; Vorinostat

Indexed keywords

CYTARABINE; GEMTUZUMAB OZOGAMICIN; HYDROXYUREA; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE KIDNEY FAILURE; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLEEDING; CLINICAL ARTICLE; CYTOPENIA; DOSE RESPONSE; DRUG EFFICACY; DYSPNEA; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INDUCTION CHEMOTHERAPY; INFECTION; KARYOTYPE; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAINTENANCE THERAPY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; RISK; SEPSIS; THROMBOCYTE;

AGED; AGED, 80 AND OVER; AMINOGLYCOSIDES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; HYDROXAMIC ACIDS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PROGNOSIS; REMISSION INDUCTION; SURVIVAL RATE;

EID: 84860595206     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.055822     Document Type: Article

References (22)

1. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, et al. SEER Cancer Statistics Review, 1975-2008, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2008/.
2. Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE, et al. Age and acute myeloid leukemia. Blood. 2006;107(9):3481-3485.
3. Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453-474.
4. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™): Acute myeloid leukemia. Version 2. 2011. Available from: www.nccn.org
5. Linenberger ML. CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance. Leukemia. 2005;19(2): 176-182.
6. Abutalib SA, Tallman MS. Monoclonal antibodies for the treatment of acute myeloid leukemia. Curr Pharm Biotechnol. 2006;7(5):343-369.
7. Pagano L, Fianchi L, Caira M, Rutella S, Leone G. The role of Gemtuzumab Ozogamicin in the treatment of acute myeloid leukemia patients. Oncogene. 2007;26(25):3679-3690.
8. Hütter ML, Schlenk RF. Gemtuzumab ozogamicin in non-acute promyelocytic acute myeloid leukemia. Expert Opin Biol Ther. 2011;11(10):1369-1380.
9. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006;5 (9):769-784.
10. ten Cate B, Samplonius DF, Bijma T, de Leij LF, Helfrich W, Bremer E. The histone deacetylase inhibitor valproic acid potently augments gemtuzumab ozogamicin-induced apoptosis in acute myeloid leukemic cells. Leukemia. 2007;21(2):248-252.
11. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-951.
12. Mrózek K, Heerema NA, Bloomfield CD. Cytogenetics in acute leukemia. Blood Rev. 2004;18(2):115-136.
13. Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH, et al. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003;21(24):4642-4649.
14. Chevallier P, Prebet T, Pigneux A, Hunault M, Delaunay J, Perry F, et al. Influence of NPM1 and FLT3-ITD status on outcome in relapsed/refractory AML patients receiving salvage therapy including gemtuzumab ozogamicin. Leukemia. 2010;24(2):467-469.
15. Pfizer Inc. 2010. Available from: http://media.pfizer.com/files/products/mylotarg_hcp_letter.pdf
16. Prebet T, Vey N. Vorinostat in acute myeloid leukemia and myelodysplastic syndromes. Expert Opin Investig Drugs. 2011;20(2):287-295.
17. Estey EH, Thall PF, Giles FJ, Wang XM, Cortes JE, Beran M, et al. Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and highrisk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside. Blood. 2002;99(12):4343-4349.
18. Amadori S, Suciu S, Stasi R, Willemze R, Mandelli F, Selleslag D, et al. Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto Leukemia Groups. Leukemia. 2005;19(10): 1768-1773.
19. Nabhan C, Rundhaugen LM, Riley MB, Rademaker A, Boehlke L, Jatoi M, et al. Phase II pilot trial of gemtuzumab ozogamicin (GO) as first line therapy in acute myeloid leukemia patients age 65 or older. Leuk Res. 2005;29(1):53-57.
20. Walter RB, Appelbaum FR, Tallman MS, Weiss NS, Larson RA, Estey EH. Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm. Blood. 2010;116(14):2420-2428.
21. Burnett AK, Hills RK, Milligan D, Kjeldsen L, Kell J, Russell NH, et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol. 2011;29(4):369-377.
22. Wathen JK, Thall PF, Cook JD, Estey EH. Accounting for patient heterogeneity in phase II clinical trials. Stat Med. 2008;27 (15):2802-2815.